Eloxatin Adjuvant Indication Could Nearly Double Sanofi’s Target Market
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Synthelabo’s pending NDA for use of Eloxatin in the adjuvant colorectal cancer setting could roughly double the potential patient population for the oncologic.
You may also be interested in...
Eloxatin Symptom-Based Clinical Benefit Could Support Full Approval
Demonstration of symptom-based clinical benefit could be used to support full approval of Sanofi-Synthelabo’s second-line colorectal cancer therapy Eloxatin, FDA indicated in review documents for the Aug. 9, 2002, accelerated approval.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product